# US 11,028,387 B2 · Double-stranded agents for delivering therapeutic oligonucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,387 B2
- Document ID: US11028387B2
- Status: Granted
- Kind: B2
- Application number: 14/892,664
- Filed: 2014-05-30
- Published: 2016-05-26
- Granted: 2021-06-08
- Earliest claimed: 2013-05-30
- Assignees: National University Corporation Tokyo Medical and Dental University
- Applicants: National University Corporation Tokyo Medical and Dental University
- Inventors: Takanori Yokota; Kazutaka Nishina; Kotaro Yoshioka; Hidehiro Mizusawa
- Web page: https://patentgrep.com/patent/US11028387B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are double-stranded nucleic acid agents that can deliver a therapeutic oligonucleotide within a biological sample, and methods for using the same. In one embodiment, the double-stranded nucleic acid agent comprises a first strand comprising a first RNA region, and a second strand comprising a first DNA region, wherein said first RNA region and said first DNA region are hybridized as a RNA/DNA heteroduplex. Said first strand further comprises a nucleic acid therapeutic oligonucleotide region that is capable of being cleaved from at least one nucleotide in said first RNA region. Methods for using the double-stranded nucleic acid agents include methods for delivering the therapeutic oligonucleotide as a single strand by cleaving it from at least a portion of the first RNA region. The methods further include delivering the double-stranded nucleic acid agent and thus the therapeutic oligonucleotide to a target site within the body of a treatment subject.

## Claims

### Claim 1

A double-stranded nucleic acid agent comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein:
the first nucleic acid strand comprises
(i) an RNA region with 8-11 consecutive natural RNA nucleotides that can be recognized by RNase H when the first nucleic acid strand is hybridized to the second nucleic acid strand,
(ii) a therapeutic oligonucleotide region wherein at least one internucleotide linkage at the 3′ end and at the 5′ end of the therapeutic oligonucleotide region is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group, and wherein the therapeutic oligonucleotide region is
(a) a single-stranded region that hybridizes to a precursor mRNA (pre-mRNA) or a micro-RNA, but does not hybridize to the second nucleic acid strand,
(b) a splice-switching oligonucleotide, an intron targeting gapmer, or an antagomir,
(c) linked to the 3′ end or 5′ end of the RNA region of the first nucleic acid strand, and
(d) released from the double-stranded nucleic acid agent in vivo via RNase H-mediated cleavage of the RNA region of (c), and
(e) comprised of one or more of modified nucleotides, nucleotide analogues, or DNA nucleotides comprising a phosphorothioate group, and
(iii) at least one internucleotide linkage at the 3′ end and at the 5′ end of the RNA region of the first nucleic acid strand is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group, and
the second nucleic acid strand comprises
(i) a 13 consecutive DNA/LNA gapmer or DNA/LNA mixmer region that is hybridized to the RNA region of the first nucleic acid strand and can promote the recognition of the 8-11 consecutive natural RNA nucleotides in the first nucleic acid strand by RNase H, and
(ii) at least one internucleotide linkage at the 3′ end and at the 5′ end of the second nucleic acid strand is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group,
and wherein
the double-stranded nucleic acid agent further comprises a targeting moiety which is (a) selected from a lipid, a sugar, a peptide, and a protein and (b) joined to the 3′-terminal nucleotide or the 5′-terminal nucleotide of the second nucleic acid strand, or to the 3′-terminal nucleotide or the 5′-terminal nucleotide of the first nucleic acid strand.

### Claim 2 (depends on 1)

The double-stranded nucleic acid agent according to claim 1, wherein the first nucleic acid strand comprises one or more nucleotides selected from modified RNA nucleotides and nucleotide analogs located 5′ and located 3′ to the 8-11 consecutive natural RNA nucleotides that can be recognized by RNase H.

### Claim 3 (depends on 2)

The double-stranded nucleic acid agent according to claim 2, wherein the one or more nucleotides located 5′ and located 3′ to the 8-11 consecutive natural RNA nucleotides that can be recognized by RNase H are independently selected from LNA nucleotides, BNA nucleotides, 2′-O-Me RNA nucleotides, and 2′-O-methoxyethyl RNA nucleotides.

### Claim 4 (depends on 1)

A method of delivering a therapeutic oligonucleotide to a cell comprising:
contacting with the cell a composition comprising the double-stranded nucleic acid agent according to claim 1.

### Claim 5

A double-stranded nucleic acid agent comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein:
the first nucleic acid strand comprises
(i) an RNA region with 8-11 consecutive natural RNA nucleotides that can be recognized by RNase H when the first nucleic acid strand is hybridized to the second nucleic acid strand,
(ii) the therapeutic oligonucleotide region wherein at least one internucleotide linkage at the 3′ end and at the 5′ end of the therapeutic oligonucleotide region is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group, and wherein the therapeutic oligonucleotide region is
(a) a single-stranded region that hybridizes to a precursor mRNA (pre-mRNA) or a micro-RNA, but does not hybridize to the second nucleic acid strand,
(b) a splice-switching oligonucleotide, an intron targeting gapmer, or an antagomir,
(c) linked to the 3′ end or 5′ end of the RNA region of the first nucleic acid strand, and
(d) released from the double-stranded nucleic acid agent in vivo via RNase H-mediated cleavage of the RNA region of (c), and
(e) comprised of one or more of modified nucleotides, nucleotide analogues, or DNA nucleotides comprising a phosphorothioate group, and
(iii) at least one internucleotide linkage at the 3′ end and at the 5′ end of the RNA region of the first nucleic acid strand is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group, and
the second nucleic acid strand comprises
(i) a plurality of regions consisting of 2 or 3 consecutive DNA nucleotides that hybridize to the RNA region of the first nucleic acid strand and promote the recognition of the 8-11 consecutive natural RNA nucleotides in the first nucleic acid strand by RNase H in a mammalian cell, and
(ii) at least one internucleotide linkage at the 3′ end and at the 5′ end of the second nucleic acid strand is more nuclease-resistant than a natural internucleotide linkage, wherein the at least one nuclease-resistant internucleotide linkage is a phosphorothioate group.

### Claim 6 (depends on 5)

The double-stranded nucleic acid agent according to claim 5, wherein the antagomir oligonucleotide is a mixmer, is composed of one type of nucleotide or nucleotide analogue, or is a gapmer.

### Claim 7 (depends on 6)

The double-stranded nucleic acid agent according to claim 6, wherein the antagomir oligonucleotide comprises at least one nucleotide selected from 2′-OMe RNA, MOE, CET, ENA, LNA and AmNA, and at least one internucleotide linkage is optionally phosphorothioated.